Bavarian Biotech Report 2011/2012 (7MB) - Bio M
Bavarian Biotech Report 2011/2012 (7MB) - Bio M Bavarian Biotech Report 2011/2012 (7MB) - Bio M
Select IMGM as your outsourcing partner and we willprovide you with a complete solution exactly matchingyour needs.RNA Services• Whole genome microarray screening (Agilent platform)• microRNA profiling (Agilent microarrays, TaqMan ® qPCR)• Gene expression studies (TaqMan ® qPCR, AB ViiA TM 7 System)• TaqMan ® Arrays (96- and 384-format)• RNA isolation and quality control serviceDNA Services• Next Generation Sequencing (NGS)(Roche 454 GS FLX+ & Junior, Ion Torrent PGM TM , Illumina MiSeq ® )• NGS target enrichment (amplification & hybridization)(Fluidigm Access Array TM , Ion AmpliSeq Target Selection,Agilent SureSelect, NimbleGen Sequence Capture)• NGS assay development (e.g. targeted resequencing)• NGS-based metagenomics and microbial diversity• Standard DNA sequencing (Sanger, AB 3730XL)• CNV analysis using oligo array-CGH• CNV validation with TaqMan ® Copy Number Assays• SNP genotyping (Pyrosequencer, Ta qMan ® )• Absolute quantitation of target sequences (e.g. bio-distribution)• High-resolution HLA typing• Pharmacogenetics (e.g. Affymetrix DMET TM Plus Chip)IMGM Laboratories GmbHLochhamer Str. 2982152 MartinsriedGermanyBioinformatics• Analysis of NGS data (internal & external)• Analysis of genome-wide gene expression data• Analysis of array-CGH and CNV data• Development of gene signatures (SVM algorithms)• Identification and validation of biomarkersph.: +49.89.895578.40fax: +49.89.895578.41info@imgm.comwww.imgm.comConsulting• Development & validation of NGS applications• Development and optimization of diagnostic tests• Performance optimization of instruments• Quality control studies• Biostatistics6 www.imgm.com
The Bavarian Biotechnology ClusterStrong partners make for a strong networklocations of Nuremberg-Erlangen, Wurzburg and Bayreuth.In the last few years, each of these locations hasdeveloped its own unique profile with specific on-sitecore competences, with specific infrastructural measuresand a competent local management team.PROF. DR.HORST DOMDEYSpeaker of the “BavarianBiotechnology Cluster”“Success through synergies” is the guiding principlebehind the Bavarian Cluster Initiative, where companiesbelonging to one segment of an industry regard themselvesnot as competitors, but as mutual beneficiaries, forexample through trustful cooperation (open innovation),through a shared market or through a pool of highlyqualified personnel. Most of these effects are favouredby spatial proximity, so, as a rule, a “single cluster”is delimited in terms of its location, for example, to onecity. Combining various clusters into a network can beespecially successful, as demonstrated by the Bavarianbiotechnology industry, which received special supportfrom the Bavarian Ministry of Economic Affairs betweenthe years 2006 and 2011 as part of the “Bavarian BiotechnologyCluster” (www.cluster-bayern.de).One of the initial successes of the “Bavarian BiotechnologyCluster” was its function as a “catalyst” for white, i.e.industrial, biotechnology. Bavaria’s strategically completelynew white biotechnology initiative was able to raisefunding in the order of millions from the federal andstate governments and strong commitment of chemicalcompany giants like Wacker AG and Süd-Chemie AG(now part of Clariant, Switzerland). This led to the foundationof a specific network of companies and researchinstitutes with their own network coordination (see page28). At various locations, and especially in Straubing,there are deliberate efforts to promote a large variety ofprojects devoted to industrial applications, for example,in the field of renewable raw materials.Munich has concentrated on drug development for manydecades and in 2010 sharpened its profile in the field of“personalized medicine” even further by winning anaward in the “Leading-Edge Cluster Competition“ heldby the German Federal Ministry of Education and Research.Under the title “m 4 – Personalized Medicine”, thismajor investment project attracts funding to a total ofalmost € 100 million from the Federal Government, theFree State of Bavaria and industry, which is channelledinto separate cooperative research projects, as well asinto infrastructural measures, for example, the newconsortium of tissue banks, the Munich-Biobank-Alliance.Equally successful in the Leading-Edge Cluster Competitionwas Nuremberg-Erlangen, a Centre of Excellencefor Medical Technology that is able to use to its advantagea tight network linking science, business, hospitals andcare facilities along with the innovative strength of theSMEs. The so called “Medical Valley” combines worldleading big and smaller enterprises like Siemens or Wave.Wurzburg has successfully established itself as a Centreof Excellence for biomedical research and Bayreuth isstrong in the field of materials research, as well as scoringhighly with interesting discoveries in the biology ofphotosynthesis and its technical exploitation.With the injection of funds from the Bavarian Ministry ofEconomic Affairs, a great deal has been achieved and alot of wheels have been set in motion. To make sure theycontinue rolling, the “Bavarian Biotechnology Cluster”will go on being promoted as a network in future. Eachlocation contributes its own individual strengths to thisnetwork and can profit from its combined efforts, withBio M GmbH serving as a central point of exchange andcontact. I am convinced that the success of each separatelocal player impacts positively on the entire network andthat we are well positioned to continue down the road tosuccess that we have taken together – to further increasethe attractiveness of Bavarian Biotechnology!Red pharmaceutical biotechnology is still networkedwithin the “Bavarian Biotechnology Cluster” and Bio MBiotech Cluster Development GmbH coordinates the welldeveloped Bavarian Biotech locations of Munich-Martinsriedand Regensburg as well as the up-and-comingProf. Dr. Horst DomdeySpeaker of the „Bavarian Biotechnology Cluster“7
- Page 2 and 3: Our research benefits your health.T
- Page 4 and 5: ImprintEditorial staff: Georg Kää
- Page 8 and 9: The 2011 Biotech Year in Bavaria -A
- Page 10 and 11: Due to this focus that was establis
- Page 12 and 13: Furthermore, the continued interest
- Page 14 and 15: Last but not least, the IZB start-u
- Page 16 and 17: Company FoundationsMerck-Sharp & Do
- Page 18 and 19: Total number of employees in the Ba
- Page 20 and 21: PHASE II4SC: Hepatocellular carcino
- Page 22 and 23: Deals, Cooperation, Mergers, Financ
- Page 24 and 25: M&A-ActivityIn early 2011 the acqui
- Page 26: Due to the increasing number of new
- Page 29: one so called “innovation allianc
- Page 32 and 33: 4SC AGBIOTECH THERAPEUTICS & DIAGNO
- Page 34 and 35: Contact:Dr. Luc St-OngeFraunhoferst
- Page 36 and 37: Contact:Dr. Lars WassillWerkstr. 2D
- Page 38 and 39: Apceth GmbH & Co. KGBIOTECH THERAPE
- Page 40 and 41: Contact:Dr. Gundel HagerBahnhofstr.
- Page 42 and 43: Bernina Plus GmbHBIOTECH THERAPEUTI
- Page 44 and 45: Biontex Laboratories GmbHBIOTECH DE
- Page 46 and 47: Carl Zeiss MicroImaging GmbHBIOTECH
- Page 48 and 49: ChemDiv, Inc.CROContact:Dr. Anna Ni
- Page 50 and 51: conoGenetix biosciences GmbHBIOTECH
- Page 52 and 53: CoreLab Partners Europe GmbHCROCont
- Page 54 and 55: Davids Biotechnologie GmbHBIOTECH D
Select IMGM as your outsourcing partner and we willprovide you with a complete solution exactly matchingyour needs.RNA Services• Whole genome microarray screening (Agilent platform)• microRNA profiling (Agilent microarrays, TaqMan ® qPCR)• Gene expression studies (TaqMan ® qPCR, AB ViiA TM 7 System)• TaqMan ® Arrays (96- and 384-format)• RNA isolation and quality control serviceDNA Services• Next Generation Sequencing (NGS)(Roche 454 GS FLX+ & Junior, Ion Torrent PGM TM , Illumina MiSeq ® )• NGS target enrichment (amplification & hybridization)(Fluidigm Access Array TM , Ion AmpliSeq Target Selection,Agilent SureSelect, NimbleGen Sequence Capture)• NGS assay development (e.g. targeted resequencing)• NGS-based metagenomics and microbial diversity• Standard DNA sequencing (Sanger, AB 3730XL)• CNV analysis using oligo array-CGH• CNV validation with TaqMan ® Copy Number Assays• SNP genotyping (Pyrosequencer, Ta qMan ® )• Absolute quantitation of target sequences (e.g. bio-distribution)• High-resolution HLA typing• Pharmacogenetics (e.g. Affymetrix DMET TM Plus Chip)IMGM Laboratories GmbHLochhamer Str. 2982152 MartinsriedGermany<strong>Bio</strong>informatics• Analysis of NGS data (internal & external)• Analysis of genome-wide gene expression data• Analysis of array-CGH and CNV data• Development of gene signatures (SVM algorithms)• Identification and validation of biomarkersph.: +49.89.895578.40fax: +49.89.895578.41info@imgm.comwww.imgm.comConsulting• Development & validation of NGS applications• Development and optimization of diagnostic tests• Performance optimization of instruments• Quality control studies• <strong>Bio</strong>statistics6 www.imgm.com
Change language